Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719160 · ClinicalTrials.gov registry record · Phase 4
The Effect of Protein on Calcium Absorption and Gastric Acid Production
A Phase 4 study of Osteoporosis, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00719160 is a Phase 4 study of Osteoporosis that has completed, run by Yale University. The registered enrollment target is 12 participants, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00719160, a Phase 4 study of Osteoporosis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether dietary protein-induced changes in gastric acid secretion explain the observed changes in intestinal calcium absorption.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG esomeprazole
Study Locations (1)
Connecticut
- Yale New Haven Hospital Hospital Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719160
The ClinicalTrials.gov registry entry for NCT00719160 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00719160 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00719160 about?
NCT00719160 is a clinical study titled "The Effect of Protein on Calcium Absorption and Gastric Acid Production". We have established that dietary protein is an important regulator of intestinal calcium absorption in humans. However, we do not understand the mechanism by which dietary protein is affecting calcium absorption. Therefore, the purpose of this research is to evaluate whether dietary protein-induced ...
What is the current status of trial NCT00719160?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2005-01. Estimated completion is 2008-05.
What conditions does trial NCT00719160 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00719160?
The interventions under investigation include: Placebo (DRUG), esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00719160?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00719160 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.